COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 9 FDA records to the applicant name Lenstec, Inc.. It includes 1 original PMA approval. 4 entries are PMA supplements. 4 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Jul 22, 2022 to Oct 23, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code MFK appears in 6 of the 9 linked filings. The collection spans 2 FDA product codes and 2 original PMA application families. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P200020, with 6 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 1 linked filing has a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 1765 Commerce Ave. N, St. Petersburg, FL, 33716. Recorded on P200020/S013, decision dated Oct 23, 2026.
Device categories in this collection
Lens, Multifocal Intraocular; Intraocular Lens.
Changes described in PMA records
The FDA recorded an approval decision on 2026-10-23 for P200020/S013, a supplement to the ClearView™ HD intraocular lens (IOL) held by Lenstec, Inc. The supplement was filed under the Normal 180 Day Track with the stated reason Change Design/Components/Specifications/Material, and the device sits in the multifocal intraocular lens category (product code MFK) within the ophthalmic specialty.
The recorded statement describes the supplement as covering the ClearView™ HD IOL as a combination of the haptic design of the ClearView™ 3 IOL with the optical design of the Softec HD IOL. That describes a design change to the lens rather than a new approval of an entire system. The source record does not include supporting documents, so the specific optical or haptic parameters changed, and any clinical data reviewed, remain unknown.
FDA approval-order wording
approval for the ClearView HD Intraocular Lens (IOL) as a combination of the haptic design of the ClearView 3 IOL with the optical design of the Softec HD IOL
Oct 23, 2026 · Normal 180 Day TrackFDA’s recorded scope: the addition of a new moist heat (steam) sterilizer, and associated increased maximum sterilization load size, for routine terminal sterilization of the subject intraocular lens devices
Apr 15, 2026 · 30-Day NoticeFDA’s recorded scope: the addition of a new moist heat (steam) sterilizer, and associated increased maximum sterilization load size, for routine terminal sterilization of the subject intraocular lens devices
Apr 15, 2026 · 30-Day NoticeFDA’s recorded scope: approval for an extension of the power range from +15.0 through +30.0D to +10.0 through +36.0D for the ClearView 3 intraocular lenses (IOLs)
Mar 25, 2026 · Real-Time ProcessFDA’s recorded scope: approval for a different material vial stopper from an alternate supplier.
Dec 4, 2025 · Normal 180 Day TrackSubsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.